CLINICAL_TRIALS
trial_result
· 2023-06-29
Clinical Trial Update: CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacks [Phase 3]
Summary
Phase 3 trial update for garadacimab (CSL312) in preventing hereditary angioedema attacks has completed with results posted in 2023.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: CSL Behring | Conditions: Hereditary Angioedema | Phase 3 | Status: COMPLETED | Results posted: 2023-06-29